OncoSec Medical Inc (ONCSQ)

[InTheTrenches]

This is significant. Responses in a 2nd solid tumor indication (Triple-Negative Breast Cancer, Melanoma), albeit in a small number of patients.

Patients were chemotherapy-refractory patients (heavily treated), had only a single cycle of treatment with IL-12, and 2 out of 5 patients experienced a robust objective response.

Note that this is also with a 2nd checkpoint inhibitor, Opdivo. Melanoma trials were with Keytruda.

This opens the door for potential bidding war for a partnership between $BMY and $MRK for $ONCS electroporation treatment.